MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 28.71M | 27.86M | 27.43M | 24.51M | 21.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.71M | 27.86M | 27.43M | 24.51M | 21.93M |
| Cost of Revenue | 17.97M | 16.24M | 17.79M | 16.70M | 17.45M |
| Gross Profit | 10.74M | 11.62M | 9.65M | 7.81M | 4.49M |
| SG&A Expenses | 14.38M | 15.04M | 16.72M | 15.00M | 17.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -51.10K | -234.20K | -112.30K | 33.80K | 152.90K |
| Total Operating Expenses | 32.58M | 31.28M | 34.63M | 31.94M | 34.96M |
| Operating Income | -3.88M | -3.42M | -7.20M | -7.44M | -13.03M |
| Income Before Tax | -8.98M | -10.17M | -10.43M | -10.04M | -11.79M |
| Income Tax Expenses | -200.70K | -202.90K | -202.90K | -202.90K | -6.60K |
| Earnings from Continuing Operations | -8.78 | -9.97 | -10.23 | -9.83 | -11.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.78M | -9.97M | -10.23M | -9.83M | -11.79M |
| EBIT | -3.88M | -3.42M | -7.20M | -7.44M | -13.03M |
| EBITDA | -1.90M | -1.36M | -5.15M | -5.60M | -11.37M |
| EPS Basic | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 1.66B | 1.65B | 1.63B | 1.51B | 1.36B |
| Average Diluted Shares Outstanding | 1.66B | 1.65B | 1.63B | 1.51B | 1.36B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
